Document Detail


Effects of angiotensin receptor blockade (ARB) on mortality and cardiovascular outcomes in patients with long-term haemodialysis: a randomized controlled trial.
MedLine Citation:
PMID:  23355629     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
BackgroundHypertension is a major risk factor for death and cardiovascular disease (CVD) in patients undergoing chronic haemodialysis (HD), but there is uncertainty surrounding the effects of blood pressure (BP) lowering on this high-risk patient group.MethodsIn a multicenter, prospective, randomized, open-label, blinded-endpoint trial, 469 patients with chronic HD and elevated BP (140-199/90-99 mmHg) were assigned to receive the angiotensin receptor blockade (ARB) olmesartan (at a dose of 10-40 mg daily; n = 235) or another treatment that does not include angiotensin receptor blockers and angiotensin-converting enzyme (ACE) inhibitors (n = 234). The primary outcomes were the following: (i) composite of death, nonfatal stroke, nonfatal myocardial infarction and coronary revascularization and (ii) all-cause death.ResultsDuring a mean follow-up of 3.5 years, the mean BP was 0.9/0.0 mmHg lower in the olmesartan group than in the control group (not significant). A total of 68 patients (28.9%) in the olmesartan group and 67 patients (28.6%) in the control group had subsequent primary composite endpoints [hazard ratio (HR) in the olmesartan group 1.00, 95% confidence interval (CI) 0.71-1.40, P = 0.99]. All-cause deaths occurred in 38 patients (16.2%) in the olmesartan group and 39 (16.7%) in the control group (HR, 0.97; 95% CI, 0.62-1.52, P = 0.91). Olmesartan did not alter the risks of serious adverse events.ConclusionsBP-lowering treatment with an ARB did not significantly lower the risks of major cardiovascular events or death among patients with hypertension on chronic HD. (Cochrane Renal Group Prospective Trial Register number CRG010600030).
Authors:
Kunitoshi Iseki; Hisatomi Arima; Kentaro Kohagura; Ichiro Komiya; Shinichiro Ueda; Kiyoyuki Tokuyama; Yoshiki Shiohira; Hajime Uehara; Shigeki Toma;
Related Documents :
15094729 - The natural history of vigabatrin associated visual field defects in patients electing ...
17525649 - Long-term outcome in ocular intractable surface disease with seoul-type keratoprosthesis.
12441719 - Long-term follow-up of patients with serpinginous choroiditis.
7315219 - Inherited retinal detachment.
19668569 - Inhibition of surgically induced miosis and prevention of postoperative macular edema w...
24622429 - Safety and efficacy of a novel abluminal groove-filled biodegradable polymer sirolimus-...
21905449 - Grinding it out: wavefront spectacle lens in clinical practice.
10609499 - Hormone replacement therapy after uterine leiomyosarcoma treatment. case reports.
23106799 - The impact of body mass index on surgical outcomes of robotic partial nephrectomy.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2013-1-25
Journal Detail:
Title:  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association     Volume:  -     ISSN:  1460-2385     ISO Abbreviation:  Nephrol. Dial. Transplant.     Publication Date:  2013 Jan 
Date Detail:
Created Date:  2013-1-28     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  8706402     Medline TA:  Nephrol Dial Transplant     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
1Dialysis Unit, University Hospital of the Ryukyus, Nishihara, Okinawa, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Comparison of absolute serum creatinine changes versus Kidney Disease: Improving Global Outcomes con...
Next Document:  Molecular pathways: adiponectin and leptin signaling in cancer.